Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance

S Narayanan, CY Cai, YG Assaraf, HQ Guo… - Drug Resistance …, 2020 - Elsevier
Drug resistance is a major obstacle in the field of pre-clinical and clinical therapeutics. The
development of novel technologies and targeted therapies have yielded new modalities to …
被引用次数：226 相关文章

Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.

S Narayanan, CY Cai, YG Assaraf, HQ Guo… - … and Commentaries in …, 2019 - europepmc.org
Drug resistance is a major obstacle in the field of pre-clinical and clinical therapeutics. The
development of novel technologies and targeted therapies have yielded new modalities to …
[PDF] google.com

[PDF][PDF] Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance

S Narayanan, CY Cai, YG Assaraf, HQ Guo… - Drug Resistance …, 2020 - drive.google.com
Drug resistance is a major obstacle in the field of pre-clinical and clinical therapeutics. The
development of novel technologies and targeted therapies have yielded new modalities to …

[引用][C] Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance

S Narayanan, CY Cai, YG Assaraf, HQ Guo… - Drug Resistance …, 2020 - cir.nii.ac.jp
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …

Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance

S Narayanan, CY Cai, YG Assaraf… - Drug resistance …, 2020 - pubmed.ncbi.nlm.nih.gov
Drug resistance is a major obstacle in the field of pre-clinical and clinical therapeutics. The
development of novel technologies and targeted therapies have yielded new modalities to …
[PDF] ltdcdn.com

[PDF][PDF] Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance

S Narayanana, CY Caia, YG Assarafb, HQ Guoc… - 2019 - uploadfile.ltdcdn.com
Drug resistance is a major obstacle in the field of pre-clinical and clinical therapeutics. The
development of novel technologies and targeted therapies have yielded new modalities to …